N/A
Completed N=116
Tygacil Drug Use Investigation
Intra-Abdominal Infections · Skin Disease, Infectious
Source: ClinicalTrials.gov NCT01789905 ↗
Enrolled (actual)
116
Serious AEs
42.2%
Results posted
Dec 2018
Primary outcomePrimary: Number of Participants With Adverse Drug Reaction (ADR) — 41; 15 Participants
Summary
Secondary Data Collection Study; safety and effectiveness of Tigecycline .under Japanese medical practice
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Drug Reaction (ADR) |
41; 15 | — |
| SECONDARY Clinical Response Rate |
73.9 | — |
| SECONDARY Clinical Response Rate of Cure |
59.0 | — |
Eligibility Criteria
Inclusion Criteria
- All patients who are prescribed tigecycline (Tygacil).
Exclusion Criteria
- Subject who have not been prescribed tigecycline (Tygacil).
Data sourced from ClinicalTrials.gov (NCT01789905). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.